Faculty of Medicine Social Medicine Social MedicineProfessor
Last Updated :2025/06/07

■Researcher basic information

Degree

  • Ph.D.(Medical Science), Keio University, Feb. 2015

Researchmap personal page

Researcher number

  • 60624426

Research Keyword

  • 医療政策
  • 社会保障
  • 医療保険
  • 診療報酬
  • 介護保険
  • 介護報酬
  • 費用対効果評価
  • 医療技術評価
  • がん対策
  • がん検診

Research Field

  • Life sciences, Hygiene and public health (non-laboratory)
  • Life sciences, Healthcare management, medical sociology

■Career

Career

  • Aug. 2024 - Present
    Hokkaido University, 大学院医学研究院 社会医学分野 医療政策評価学教室, 教授, Japan
  • Nov. 2021 - Jul. 2024
    Ministry of Health,Labour and Welfare, 老健局老人保健課, 課長
  • Aug. 2020 - Oct. 2021
    厚生労働省, 健康局がん・疾病対策課, 課長
  • Apr. 2020 - Jul. 2020
    厚生労働省, 医薬・生活衛生局血液対策課, 課長
  • Nov. 2019 - Mar. 2020
    National Institute of Public Health, 企画調整主幹
  • Jul. 2019 - Oct. 2019
    内閣官房, 健康・医療戦略室, 参事官
  • Aug. 2017 - Jun. 2019
    厚生労働省, 保険局医療課, 企画官
  • Apr. 2014 - Jul. 2017
    千葉県, 健康福祉部, 保健医療担当部長
  • Jul. 2013 - Mar. 2014
    厚生労働省, 医薬食品局審査管理課医療機器審査管理室, 室長
  • Aug. 2011 - Jun. 2013
    厚生労働省, 大臣官房厚生科学課, 主任科学技術調整官
  • Apr. 2011 - Jul. 2011
    厚生労働省, 大臣官房厚生科学課, 課長補佐
  • Apr. 2009 - Mar. 2011
    三重県, 健康福祉部, 医療政策監 兼 保健・医療分野総括室長
  • Apr. 2007 - Mar. 2009
    厚生労働省, 老健局老人保健課, 課長補佐
  • Mar. 2005 - Mar. 2007
    環境省, 環境保健部企画課特殊疾病対策室, 室長補佐
  • Sep. 2004 - Feb. 2005
    環境省, 環境保健部環境安全課環境リスク評価室, 室長補佐
  • Sep. 2003 - Aug. 2004
    London School of Hygiene and Tropical Medicine, United Kingdom
  • Sep. 2002 - Aug. 2003
    厚生労働省, 社会援護局障害保健福祉部精神保健福祉課, 社会復帰対策専門官, Japan
  • Jul. 2002 - Aug. 2002
    厚生労働省, 保険局医療課, 課長補佐
  • Apr. 1999 - Jun. 2002
    厚生労働省, 保険局医療課, 主査
  • May 1998 - Sep. 1999
    国立病院東京医療センター, 総合診療科
  • Oct. 1998 - Mar. 1999
    厚生省, 大臣官房厚生科学課, 係員
  • May 1997 - Apr. 1998
    国立病院東京災害医療センター, Japan
  • Apr. 1997 - Apr. 1997
    国立公衆衛生院, 研修生, Japan

Educational Background

  • Aug. 2003 - Aug. 2004, London School of Hygiene and Tropical Medicine, Master of Science, Environmental Epidemiology, United Kingdom
  • Apr. 1991 - Mar. 1997, 慶雄義塾大学, 医学部, 医学科, Japan

■Research activity information

Papers

  • Association Between Undernutrition and the Number of Molar Occlusions in Older Persons Requiring Care in Long-Term Care Insurance Facilities.
    Koji Takahashi, Yutaka Watanabe, Takuma Okumura, Yasushi Tamada, Misuzu Sato, Masanori Iwasaki, Maki Shirobe, Hirohiko Hirano, Yoshihiro Kugimiya, Masako Kishima, Kayoko Ito, Yasuyuki Iwasa, Yoshihiko Watanabe, Shinsuke Mizutani, Kazuharu Nakagawa, Shigekazu Komoto, Yutaka Yamazaki
    Nutrients, 17, 4, 10 Feb. 2025, [International Magazine]
    English, Scientific journal, Background/Objectives: Undernutrition increases the mortality risk in older persons requiring long-term care; further, it is associated with oral functions such as swallowing and chewing. Moreover, occlusion affects oral function and is crucially involved in nutritional intake. The present study aimed to examine the association between the number of molar occlusions and undernutrition according to body mass index (BMI) in older persons requiring long-term care. Methods: Japanese older persons requiring long-term care were categorized based on BMI (<20 kg/m2 vs. 20 kg/m2). We examined the association between undernutrition and the number of molar occlusions (one in each of the left and right premolars and molars, for a total of four). Results: Among 893 included participants, 440 (49.3%) had BMI < 20 kg/m2 and 453 (50.7%) had BMI > 20 kg/m2. Binomial logistic regression analysis revealed that BMI < 20 kg/m2 was significantly associated with increased number of molar occlusions (odds ratio: 0.52-0.70, 95% CI: 0.28-1.00). This indicated that a decrease in the number of molar occlusions was associated with malnutrition as determined through BMI in older persons requiring long-term care and residing in long-term care insurance facilities in Japan. Conclusions: Our findings suggest that maintaining occlusal support may help maintain nutritional status in older persons requiring long-term care.
  • Japan's Long-Term Care Issues: Construction and Adoption of the LIFE Database for Establishing Evidence-Based Care Practice.
    Hiroyuki Shimada, Junichi Nitta, Hiroshi Sasaki, Taeko Watanabe, Takashi Sakamoto, Shigekazu Komoto, Hidenori Arai
    Journal of the American Medical Directors Association, 23, 8, 1433, 1434, Aug. 2022, [International Magazine]
    English
  • Japanese National Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease.
    Masanari Kuwabara, Megumu Mori, Shigekazu Komoto
    Circulation, 143, 20, 1929, 1931, 18 May 2021, [International Magazine]
    English, Scientific journal
  • Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Masataka Hasegawa, Shigekazu Komoto, Takeru Shiroiwa, Takashi Fukuda
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 23, 1, 43, 51, Jan. 2020, [International Magazine]
    English, Scientific journal, In April 2019, Japan formally introduced health technology assessment (HTA) and, more specifically, a cost-effectiveness analysis, to inform healthcare decision making, mainly when it comes to the pricing of new technologies. This article provides an overview of this new policy, which was implemented formally after a pilot program. In the fiscal year (FY) 2012, discussions on cost-effectiveness assessments were initiated in Japan. After 7 years of deliberations, a cost-effectiveness assessment was implemented formally in April 2019. In Japan, the cost-effectiveness analysis has been used to inform price adjustments of healthcare technologies, although it has not yet been used for decision making on insurance coverage. Selection criteria were established because not all drugs and medical devices could be evaluated owing to a shortage of experts. Exclusion criteria have also been applied to prevent access restriction. The scope of the evaluation's price adjustment target is limited to part of the product price. If the cost per quality-adjusted life-year (QALY) threshold falls below \5 million per QALY, the price adjustment rate changes stepwise according to the cost per QALY. In addition to price reduction, a price-raising scheme has also been implemented for scenarios where products are evaluated to be highly cost-effective and innovative. This article describes the first formally implemented HTA system in Japan. Although it is too early to make any conclusions about its effect, the Japan-specific context makes this system unique. To fully understand the opportunities and challenges of the new system, it is vital that Japan accumulates experience with this system and develops human resources in health economic evaluation.
  • Exploring the Application of Cost-Effectiveness Evaluation in the Japanese National Health Insurance System.
    Hisayuki Ogura, Shigekazu Komoto, Takeru Shiroiwa, Takashi Fukuda
    International journal of technology assessment in health care, 35, 6, 452, 460, 2019, [International Magazine]
    English, Scientific journal, OBJECTIVES: Advances in health care due to the development and introduction of new drugs and medical devices have brought considerable benefits to people and patients in terms of upgraded quality of life and extended years of survival. However, some are concerned that the very advancement of health care would increase further the inflation of national healthcare costs. In response to these concerns, Japan's Central Social Insurance Medical Council ("Chuikyo") began in 2012 to examine how cost-effectiveness evaluation might be applied to the national health insurance system, and has been working toward establishing a system for its usage. METHODS: Cost-effectiveness evaluation was adopted on a trial basis in fiscal year (FY) 2016, targeting seven drugs and six medical devices. Analyses and re-analyses were performed by manufacturers and a public expert organization, respectively. Based on these analyses, a cost-effectiveness evaluation expert organization conducted an overall assessment ("appraisal"). Results of the evaluation were used to adjust the prices of the target items. RESULTS: Following the trial adoption of cost-effectiveness evaluation, price adjustments were performed for three items in April 2018. Meanwhile, a decision was also made to examine seven items for which technical requirements were identified due to differences in the understanding of analysis methods between involved parties. CONCLUSIONS: The Chuikyo will examine how to meet the newly identified technical requirements and discuss specific details with regard to establishing a system that incorporates cost-effectiveness evaluation. The Chuikyo plans to reach a conclusion by the end of FY 2018.
  • Effect size and cost-effectiveness estimates of breast and cervical cancer screening reminders by population size through complete enumeration of Japanese local municipalities.
    Shigekazu Komoto, Yuji Nishiwaki, Tomonori Okamura, Hideo Tanaka, Toru Takebayashi
    BMC public health, 14, 43, 43, 16 Jan. 2014, [International Magazine]
    English, Scientific journal, BACKGROUND: Client reminders are known to increase cancer screening attendance rates. However, there are significant costs associated with them, and their effect by population size is unknown. METHODS: In 2007 and 2008, the Japanese Government surveyed breast and cervical cancer screening in every municipality in Japan. From the results, we selected all 1,464 municipalities that carried out both screening types. We examined whether changes in screening attendance rates between 2007 and 2008 were associated with client reminders, number of public health nurses per 100,000 population, financial strength index, and 2007 attendance rates for different population sizes. We then calculated cost-effectiveness estimates of client reminders by population size and screening type. RESULTS: Client reminders were associated with increased attendance rates in populations <100,000. For populations of 50,000-100,000, there was a 2.76% increase in breast cancer screening (95% CI: 0.41, 5.11), and a 2.25% increase in cervical cancer screening (95% CI: 0.89, 3.61). The incremental cost per additional attendance was higher in populations <50,000 than in populations of 50,000-100,000 (breast, $100 versus $54; cervical, $149 versus $67 respectively). CONCLUSIONS: Client reminders for breast and cervical cancer screening increased attendance rates in smaller municipalities in Japan.
  • Human intake of PCDDs, PCDFs, and dioxin like PCBs in Japan, 2001 and 2002.
    Yukie Mato, Noriyuki Suzuki, Noritaka Katatani, Kiwao Kadokami, Takeshi Nakano, Shinji Nakayama, Hideaki Sekii, Shigekazu Komoto, Satoru Miyake, Masatoshi Morita
    Chemosphere, 67, 9, S247-55, Apr. 2007, [International Magazine]
    English, Scientific journal, PCDDs, PCDFs, and dioxin like PCBs (dioxin) surveillance results derived from regular environmental monitoring as well as other dioxin surveys by national and local governmental bodies in Japan were collected and analyzed. Several thousand data for air and soil in fiscal year 2001 (from 01/04/2001 to 31/03/2002) and 2002, water (from the sea, rivers and lakes), sediment (from the sea, rivers and lakes), ground water, aquatic organisms, purified water from water purification plants, raw water from water purification plants, human breast milk, and human blood in fiscal 2001, and total diet study (TDS) and various kinds of foodstuff in fiscal 1998-2002 were collected. Average human uptake of dioxin in Japan in fiscal 2001 was estimated at 1.68 pg-TEQ/kg-bw/day, while uptake in fiscal 2002 was estimated at 1.52 pg-TEQ/kg-bw/day. Diet accounted for more than 90% of the total intake. Contributions of inhalation and soil ingestion were relatively small. Age-group-specific contribution of various foodstuff to total dietary intake was also estimated. The estimates of intake through fish and shellfish accounted for approximately 45-70% of total dietary intake in each age group. Monte Carlo simulation was conducted, using the data of the air and soil concentrations in fiscal 2001 and the total diet study data in fiscal 1998-2001, in order to obtain information on the variability of dioxin intake; The estimated average, median, 5th percentile and 95th percentile of the intake distribution were 1.78, 1.69, 0.95 and 2.91 pg-TEQ/kg-bw/day, respectively. This study found that the average total intake estimates in Japan in both fiscal 2001 and 2002 were estimated to be below tolerable daily intake level (TDI) defined by the Ministry of Health, Labour and Welfare, Japan (i.e. 4 pg-TEQ/kg-bw/day). The 95th percentile of the dioxin intake distributions estimated with Monte Carlo simulation using the data of the air and soil concentrations in fiscal 2001 and TDS data in fiscal 1998-2001 was also below the Japanese TDI.

Other Activities and Achievements